Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | S100A4 | P26447 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL7941475 | 0.89 | CASP6 (0.57) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL5533530 | 0.87 | S100A4 (0.46) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL1527627 | 0.82 | TSHR (0.62) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL5575186 | 0.81 | HPRT1 (0.64) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL774702 | 0.79 | TSHR (0.52) | CASP6S100A4TSHRTDP1MAPT | |
| SCHEMBL4960980 | 0.77 | TDP1 (0.66) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL11800731 | 0.77 | MEN1 (0.50) | CASP6S100A4TSHRTDP1CYP3A4 | |
| SCHEMBL5167846 | 0.76 | LMNA (0.54) | S100A4TSHRTDP1CYP3A4MEN1 | |
| SCHEMBL31677837 | 0.76 | LMNA (0.54) | S100A4TSHRTDP1CYP3A4MEN1 | |
| SCHEMBL2760792 | 0.76 | LMNA (0.54) | S100A4TSHRTDP1CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | claimed |
| EP-3415641-B1 | METHOD FOR ANALYSIS OF MOLECULES | PACIFIC BIOSCIENCES CALIFORNIA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3415641-A1 | METHOD FOR ANALYSIS OF MOLECULES | Pacific Biosciences Of California, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | VISIGEN BIOTECHNOLOGIES, INC. | 2018-04-12 | — | — | US | disclosed |
| US-9845500-B2 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis | Life Technologies Corporation (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170343479-A1 | APPARATUS AND METHOD FOR PERFORMING NUCLEIC ACID ANALYSIS | PACIFIC BIOSCIENCES CALIFORNIA INC (US) | 2017-11-30 | — | — | US | disclosed |
| US-9709503-B2 | Apparatus and method for performing nucleic acid analysis | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9588051-B2 | Apparatus and method for performing nucleic acid analysis | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170002409-A1 | APPARATUS AND METHOD FOR PERFORMING NUCLEIC ACID ANALYSIS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20160244822-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | Life Technologies Corporation | 2016-08-25 | — | — | US | disclosed |
| US-7211414-B2 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060183145-A1 | Use of reversible extension terminator in nucleic acid sequencing | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-08-17 | — | — | US | disclosed |
| US-20060061754-A1 | Arrays of optical confinements and uses thereof | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060061755-A1 | Apparatus and method for analysis of molecules | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060063264-A1 | Apparatus and method for performing nucleic acid analysis | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-03-23 | — | — | US | disclosed |
| US-20060062531-A1 | Fabrication of optical confinements | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1354064-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | Visigen Biotechnologies, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | Life Technologies Corporation | 2003-07-17 | — | — | US | disclosed |
| WO-2002044425-A2 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR ALTERING MONOMER INCORPORATION FIDELITY | VISIGEN BIOTECHNOLOGIES, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6399335-B1 | MIXING POLYMERASE AND NUCLEOSIDE TRIPHOSPHATE HAVING A GAMMA PHOSPHATE PHOSPHOESTER-LINKED FUNCTIONAL GROUP, INCUBATING SO THAT POLYMERASE CATALYZES CLEAVAGE BETWEEN ALPHA AND BETA PHOSPHATES AND LIBERATES PYROPHOSPHATE WITH FUNCTIONAL GROUP | ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180100191-A1 | ENZYMATIC NUCLEIC ACID SYNTHESIS: COMPOSITIONS AND METHODS FOR INHIBITING PYROPHOSPHOROLYSIS | RNGTT, PPA1, PNP | CASP6 3393/4885S100A4 3154/4885TSHR 3956/4885 |
| US-20030134807-A1 | Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity | RNGTT, PNP, MTAP | CASP6 3800/4885S100A4 3172/4885TSHR 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.